Abstract

Alendronate 70-mg/75-mL Drinkable Formulation

Author(s): Allen Loyd V Jr

Issue: Nov/Dec 2016 - Volume 20, Number 6

Page(s): 504

Download in electronic PDF format for $75

Abstract

A formulation for preparing Alendronate 70-mg/75-mL Drinkable Formulation. Includes ingredients, method of preparation, discussion, and references for the compounding pharmacist.

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page View/Buy	Title/Author (Click for Abstract / Details / Purchase)
Nov/Dec 2016 Pg. 504	Alendronate 70-mg/75-mL Drinkable Formulation Author(s): Allen Loyd V Jr
Nov/Dec 2004 Pg. 462-465	Basics of Compounding for Cough Author(s): Allen Loyd V Jr
May/Jun 2004 Pg. 181-185	Compounding in the Pharmacy Curriculum: Beyond the Basics Author(s): Hinkle Amanda R, Newton Gail D
May/Jun 2022 Pg. 232	Alendronate Sodium 1% Topical Dental Gel Author(s): Allen Loyd V Jr
Jan/Feb 2004 Pg. 16-21	Androgen Deficiency in Women: Understanding the Science, Controversy and Art of Treating Our Patients - Part 1 Author(s): Cutter Christopher B
Jan/Feb 2004 Pg. 10-14	Women's Oral Health: Is There a Hormonal Link? Author(s): Preckshot John
Sep/Oct 2003 Pg. 330-338	A Perspective on HRT for Women: Picking Up the Pieces After the Women's Health Initiative Trial - Part 2 Author(s): Gillson George R, Zava David T
Mar/Apr 2023 Pg. 108-112	Vulvovaginal Symptoms in a Postmenopausal Woman: A Case Study Author(s): Lima Ramona, Gonzalez Mark A, Urwin Craig, Jean Linda, Carvalho Maria, Banov Fabiana
Nov/Dec 2010 Pg. 465-471	The Clinical Use of Dehydroepiandrosterone in Postmenopausal Women Author(s): Bramwell Bethany L
Mar/Apr 2004 Pg. 96-99	Androgen Deficiency in Women: Understanding the Science, Controversy and Art of Treating Our Patients - Part 2 Author(s): Cutter Christopher B
Jan/Feb 2013 Pg. 74-85 View Sample	The Effects of Compounded Bioidentical Transdermal Hormone Therapy on Hemostatic, Inflammatory, and Immune Factors; Cardiovascular Biomarkers; Quality of Life Measures; and Health Outcomes in Perimenopausal and Postmenopausal Women Author(s): Stephenson Kenna, Neuenschwander Pierre F, Kurdowska Anna K
Jul/Aug 2008 Pg. 295-304	Transdermal Progesterone: Effects on Menopausal Symptoms and on Thrombotic, Anticoagulant, and Inflammatory Factors in Postmenopausal Women Author(s): Stephenson Kenna, Neuenschwander Pierre F, Kurdowska Anna K, Pinson Barbara, Price Carol
Sep/Oct 2007 Pg. 421	Diclofenac Sodium 75-mg/mL Injection Author(s): Allen Loyd V Jr
May/Jun 2022 Pg. 235	Chloral Hydrate 70 mg/mL Syrup Author(s): Allen Loyd V Jr
Jul/Aug 2018 Pg. 320	Metronidazole Benzoate 70 mg/mL in SyrSpend SF Oral Suspension Author(s): Allen Loyd V Jr
May/Jun 2013 Pg. 234	Mercaptopurine 75-mg Capsules Author(s): Allen Loyd V Jr
Nov/Dec 2000 Pg. 461	Progesterone Cycle Pack 35/50/75/100-mg Capsules Author(s): Allen Loyd V Jr
May/Jun 2018 Pg. 263	Erratum: Formulation: Lansoprazole 3-mg/mL Oral Suspension Author(s):
Jan/Feb 2001 Pg. 25	Book Reviews: Stability and Formulation References Author(s): Allen Loyd V Jr
May/Jun 2007 Pg. 220-225	Need for Appropriate Formulations for Children: The National Institute of Child Health and Human Development--Pediatric Formulations Initiative, Part 2 Author(s): Giacoia George P, Taylor-Zapata Perdita, Mattison Donald